MedTrace Logo

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

NCT05003531 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2024-01-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 administered in different dose regimens for the treatment of patients with plaque psoriasis

Conditions

Interventions

DRUG

IBI112 dose 2

Participants will receive placebo or dose 2 IBI112 SC

DRUG

IBI112 dose 4

Participants will receive placebo or dose 4 IBI112 SC

DRUG

IBI112 dose 1

Participants will receive placebo or dose 1 IBI112 SC

DRUG

IBI112 dose 3

Participants will receive placebo or dose 3 IBI112 SC

DRUG

placebo

Participants will receive placebo SC

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-23
Primary Completion
2022-03-25
Completion
2023-01-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05003531 on ClinicalTrials.gov